Cancer Research Institute
Clinical Trials
APEC1621K NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations.
The main goal is to find out what effect, good and/or bad effects AG-120 (ivosidenib) on your tumor. A second goal of the study is to evaluate side effects that might be caused by AG-120 (ivosidenib), which could shrink your ca ...
Association of ctDNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with advanced stage epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
To compare the levels of ctDNA and CTCs using the SIGNATERA™ test in the peripheral blood of patients during neoadjuvant chemotherapy and after IDS for advanced stage epithelial ovarian carcinoma. Blood samples will be collecte ...
AstraZeneca AB / “A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY”
We are doing this study to learn more about the effect of Ceralasertib plus Durvalumab on the inhibition of tumor growth, and also to better understand the studied disease and associated
BO40729: An Open Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech And/Or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMBRELLA B) (roll-over to YO40482)
You are being asked to take part in this research study (also known as a clinical trial) because you have cancer and you have been in an atezolizumab study (hereafter referred to as the parent study) sponsored by Genentech Inc. ...
Caris Molecular Intelligence and Caris Centers of Excellence for Precision Medicine Network Outcomes Associated Repository
The purpose of the research repository is to collect information, which will be used for research studies to evaluate how clinical outcomes relate to Caris Molecular INtelligence Services.
Duloxetine to Prevent Oxaliplatin-induced Chemotherapy-induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
This study is being because we want to find out if duloxetine can prevent oxaliplatin-induced peripheral neuropathy (also called OIPN).
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in Patients who Achieve a Pathologic Complete Response, Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to Optimize Therapy in HER2-positive Breast Cancer)
This study is being done to answer the following question. Can participants with HER2-positive breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after 12 weeks of chemotherapy ...
EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
The study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in the future. The study treatm ...
Failure of eligible Head and Neck cancer patients to participate in an adjuvant therapy transoral surgical Clinical Trial: critical associations
We invite you to take part in a research study because were diagnosed with p16 positive oropharyngeal squamous cell carcinoma and when diagnosed, you were presented with the opportunity to enroll on a clinical trial named PATHO ...